Compile Data Set for Download or QSAR
maximum 50k data
Found 1137 with Last Name = 'kobashi' and Initial = 'y'
TargetSodium/glucose cotransporter 2(Homo sapiens (Human))
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50467841(CHEMBL4284073)
Affinity DataIC50:  2nMAssay Description:Inhibition of human SGLT2 expressed in CHOK1 cells assessed as reduction in Na-dependent [14C]-methyl-alpha-D-glucopyranoside uptake after 1 hr by mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSodium/glucose cotransporter 2(Homo sapiens (Human))
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50467845(CHEMBL4288518)
Affinity DataIC50:  2nMAssay Description:Inhibition of human SGLT2 expressed in CHOK1 cells assessed as reduction in Na-dependent [14C]-methyl-alpha-D-glucopyranoside uptake after 1 hr by mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSodium/glucose cotransporter 2(Homo sapiens (Human))
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50315418((1S)-1,5-Anhydro-1-[3-(4-ethoxybenzyl)-4-methylphe...)
Affinity DataIC50:  2.30nMAssay Description:Inhibition of human SGLT2 expressed in CHOK1 cells assessed as reduction in Na-dependent [14C]-methyl-alpha-D-glucopyranoside uptake after 1 hr by mi...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558265(N-Methyl-3-[[methyl-[3-[[6-(1-H-pyrazol-5-yl)-3-py...)
Affinity DataIC50:  3nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558426(Methyl 4-hydroxy-4-[3-[[6-(1-H-pyrazol-5-yl)-3-pyr...)
Affinity DataIC50:  3nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium/glucose cotransporter 2(Homo sapiens (Human))
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50467850(CHEMBL4290854)
Affinity DataIC50:  3nMAssay Description:Inhibition of human SGLT2 expressed in CHOK1 cells assessed as reduction in Na-dependent [14C]-methyl-alpha-D-glucopyranoside uptake after 1 hr by mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSodium/glucose cotransporter 2(Homo sapiens (Human))
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50467849(CHEMBL4280615)
Affinity DataIC50:  3nMAssay Description:Inhibition of human SGLT2 expressed in CHOK1 cells assessed as reduction in Na-dependent [14C]-methyl-alpha-D-glucopyranoside uptake after 1 hr by mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558427(US11365192, Example 51-2)
Affinity DataIC50:  3.5nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium/glucose cotransporter 2(Homo sapiens (Human))
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50467840(CHEMBL4286329)
Affinity DataIC50:  4nMAssay Description:Inhibition of human SGLT2 expressed in CHOK1 cells assessed as reduction in Na-dependent [14C]-methyl-alpha-D-glucopyranoside uptake after 1 hr by mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSodium/glucose cotransporter 2(Homo sapiens (Human))
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50467843(CHEMBL4290434)
Affinity DataIC50:  4nMAssay Description:Inhibition of human SGLT2 expressed in CHOK1 cells assessed as reduction in Na-dependent [14C]-methyl-alpha-D-glucopyranoside uptake after 1 hr by mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558428(1-[4-Hydroxy-4-[3-[[6-(1-H-pyrazol-5-yl)-3-pyridin...)
Affinity DataIC50:  4.40nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium/glucose cotransporter 2(Homo sapiens (Human))
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50467854(CHEMBL4291937)
Affinity DataIC50:  5nMAssay Description:Inhibition of human SGLT2 expressed in CHOK1 cells assessed as reduction in Na-dependent [14C]-methyl-alpha-D-glucopyranoside uptake after 1 hr by mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSodium/glucose cotransporter 2(Homo sapiens (Human))
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50467842(CHEMBL4289746)
Affinity DataIC50:  5nMAssay Description:Inhibition of human SGLT2 expressed in CHOK1 cells assessed as reduction in Na-dependent [14C]-methyl-alpha-D-glucopyranoside uptake after 1 hr by mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSodium/glucose cotransporter 2(Homo sapiens (Human))
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50467851(CHEMBL4290161)
Affinity DataIC50:  5nMAssay Description:Inhibition of human SGLT2 expressed in CHOK1 cells assessed as reduction in Na-dependent [14C]-methyl-alpha-D-glucopyranoside uptake after 1 hr by mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558439(N-Methyl-N-[[3-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]o...)
Affinity DataIC50:  5.10nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558214(2,3-Difluoro-5-[3-[[6-(1H-pyrazol-5-yl)-3-pyridiny...)
Affinity DataIC50:  5.10nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4A11(Homo sapiens)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558313(2-[3-[[6-(5-Isothiazolyl)-3-pyridinyl]oxymethyl]ph...)
Affinity DataIC50:  5.30nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558338(US11365192, Example 42-16)
Affinity DataIC50:  5.70nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558218(2-Methyl-5-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]oxyme...)
Affinity DataIC50:  6.20nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558269(US11365192, Example 23-6)
Affinity DataIC50:  6.40nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM50591500(CHEMBL5195099)
Affinity DataIC50:  6.5nMAssay Description:Inhibition of human recombinant CYP4F2 using Luciferin-4F2/3 as substrate incubated for 60 mins in presence of NADPH regenerating system by luminesce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCytochrome P450 4A11(Homo sapiens)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558316(US11365192, Example 40-2)
Affinity DataIC50:  6.90nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium/glucose cotransporter 2(Homo sapiens (Human))
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50467848(CHEMBL4281880)
Affinity DataIC50:  7nMAssay Description:Inhibition of human SGLT2 expressed in CHOK1 cells assessed as reduction in Na-dependent [14C]-methyl-alpha-D-glucopyranoside uptake after 1 hr by mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSodium/glucose cotransporter 2(Homo sapiens (Human))
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50467847(CHEMBL4287309)
Affinity DataIC50:  7nMAssay Description:Inhibition of human SGLT2 expressed in CHOK1 cells assessed as reduction in Na-dependent [14C]-methyl-alpha-D-glucopyranoside uptake after 1 hr by mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSodium/glucose cotransporter 2(Homo sapiens (Human))
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50467855(CHEMBL4279495)
Affinity DataIC50:  7nMAssay Description:Inhibition of human SGLT2 expressed in CHOK1 cells assessed as reduction in Na-dependent [14C]-methyl-alpha-D-glucopyranoside uptake after 1 hr by mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558216(US11365192, Example 11-3)
Affinity DataIC50:  7.30nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4A11(Homo sapiens)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558552(US11365192, Example 75-7 | US11365192, Example 75-...)
Affinity DataIC50:  7.70nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558188(1-Acetyl-4-[8-[[6-(1H-pyrazol-5-yl)-3-pyridinyl]ox...)
Affinity DataIC50:  7.90nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4A11(Homo sapiens)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558451(1,1,1-Trifluoro-N-[[3-[[6-(1-H-pyrazol-5-yl)-3-pyr...)
Affinity DataIC50:  8.10nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4A11(Homo sapiens)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558443(2,2-Difluoro-2-[3-[[6-(1H-pyrazol-5-yl)-3-pyridiny...)
Affinity DataIC50:  8.20nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558158(US11365192, Example 1-63)
Affinity DataIC50:  8.90nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium/glucose cotransporter 2(Homo sapiens (Human))
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50467846(CHEMBL4282565)
Affinity DataIC50:  9nMAssay Description:Inhibition of human SGLT2 expressed in CHOK1 cells assessed as reduction in Na-dependent [14C]-methyl-alpha-D-glucopyranoside uptake after 1 hr by mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCytochrome P450 4A11(Homo sapiens)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558294(3-[3-[[6-(1H-Pyrazol-5-yl)-3-pyridinyl]oxymethyl]p...)
Affinity DataIC50:  9.30nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558529(US11365192, Example 72-6)
Affinity DataIC50:  9.40nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4A11(Homo sapiens)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558114(US11365192, Example 1-19)
Affinity DataIC50:  9.5nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4A11(Homo sapiens)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558295(US11365192, Example 31-2)
Affinity DataIC50:  9.80nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4A11(Homo sapiens)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558315(2-[3-[[6-(5-Oxazolyl)-3-pyridinyl]oxymethyl]phenyl...)
Affinity DataIC50:  9.90nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium/glucose cotransporter 2(Homo sapiens (Human))
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50503838(CHEMBL4450704)
Affinity DataIC50:  10nMAssay Description:Inhibition of human SGLT2 expressed in CHOK1 cells assessed as reduction in sodium-dependent glucose uptake after 1 hr in presence of [14C]-methyl-al...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558440(1,1,1-Trifluoro-3-[3-[[6-(1H-pyrazol-5-yl)-3-pyrid...)
Affinity DataIC50:  10nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558219(US11365192, Example 12-2)
Affinity DataIC50:  11nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558342(US11365192, Example 42-20)
Affinity DataIC50:  11nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4A11(Homo sapiens)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558311(2-[3-[[6-(1H-Pyrazol-4-yl)-3-pyridinyl]oxymethyl]p...)
Affinity DataIC50:  11nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4A11(Homo sapiens)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558231(US11365192, Example 18-2)
Affinity DataIC50:  12nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558533(1,1-Dioxo-3-[8-[6-(1H-pyrazol-5-yl)pyridin-3-yl]ox...)
Affinity DataIC50:  12nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558339(US11365192, Example 42-17)
Affinity DataIC50:  12nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558326(US11365192, Example 42-4)
Affinity DataIC50:  12nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4A11(Homo sapiens)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558297(US11365192, Example 31-4)
Affinity DataIC50:  12nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4A11(Homo sapiens)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558265(N-Methyl-3-[[methyl-[3-[[6-(1-H-pyrazol-5-yl)-3-py...)
Affinity DataIC50:  13nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4F2(Homo sapiens (Human))
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558222(US11365192, Example 13-2)
Affinity DataIC50:  13nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 4A11(Homo sapiens)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558230(6-[3-[[6-(1H-Pyrazol-5-yl)-3-pyridinyl]oxymethyl]p...)
Affinity DataIC50:  13nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 1137 total ) | Next | Last >>
Jump to: